Skip to Main Content

Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

  • Study HIC#:1206010476
  • Last Updated:02/22/2018

Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.

  • Age3 months - 4 years
  • GenderBoth
  • Start Date07/19/2012
  • End Date07/31/2019

Trial Purpose and Description

Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.

Eligibility Criteria

Cystic Fibrosis participants:

Inclusion Criteria:

  • laboratory diagnosis of Cystic Fibrosis

Exclusion Criteria:

  • Major organ system disease other than Cystic Fibrosis
  • History of prematurity

Non Cystic Fibrosis control participants:

Inclusion Criteria:

  • Proof of a negative newborn CF screening test

Exclusion Criteria:

  • Major organ system disease
  • History of prematurity

Sub-Investigators

For more information about this study, contact:

Or contact the Help us Discover team on: